Cargando…

PM397. Effectiveness of blonanserin in patients with schizophrenia: A systematic review and meta-analysis of direct head-to-head comparisons with other antipsychotics

Detalles Bibliográficos
Autores principales:	Kishi, T., Matsunaga, S., Hagi, K., Iwata, N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5616333/ http://dx.doi.org/10.1093/ijnp/pyw041.397

Ejemplares similares

PM423. Blonanserin augmentation in patients with schizophrenia – who is benefited from blonanserin augmentation?: An open-label, prospective, multicenter study
por: Woo, Young Sup, et al.
Publicado: (2016)

Early prediction of blonanserin response in Japanese patients with schizophrenia
por: Kishi, Taro, et al.
Publicado: (2014)

397. The Three COVID-19 Prognostic Tools (CALL, 4Cs, NLR): Head-to-Head Comparison
por: Doumat, George, et al.
Publicado: (2023)

PM498. Investigation of feelings toward taking blonanserin and risperidone in schizophrenia patients: part 2
por: Shoji, Yoshihisa, et al.
Publicado: (2016)

A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders
por: Kishi, Taro, et al.
Publicado: (2016)

PM429. Comparison of haloperidol and blonanserin on development of dopamine supersensitivity after chronic treatment
por: Hashimoto, Takashi, et al.
Publicado: (2016)

Cardiometabolic Risks of Blonanserin and Perospirone in the Management of Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Kishi, Taro, et al.
Publicado: (2014)

Blonanserin Augmentation of Atypical Antipsychotics in Patients with Schizophrenia-Who Benefits from Blonanserin Augmentation?: An Open-Label, Prospective, Multicenter Study
por: Woo, Young Sup, et al.
Publicado: (2016)

S220. BLONANSERIN AUGMENTATION IN PATIENTS WITH SCHIZOPHRENIA – WHO IS BENEFITED FROM BLONANSERIN AUGMENTATION? AN OPEN-LABEL, PROSPECTIVE, MULTI-CENTER STUDY
por: Bahk, Won-Myong, et al.
Publicado: (2018)

Switching Antipsychotics to Blonanserin in Patients with Schizophrenia: An Open-label, Prospective, Multicenter Study
por: Woo, Young Sup, et al.
Publicado: (2019)

PM390. Comparison of Fast Versus Slow Strategy in Switching Schizophrenia Patients to Aripiprazole from Other Antipsychotics
por: Hwang, Tzung-Jeng, et al.
Publicado: (2016)

Profile of blonanserin for the treatment of schizophrenia
por: Tenjin, Tomomi, et al.
Publicado: (2013)

PM393. Antipsychotic polypharmacy patterns and antipsychotic psychiatric medication adherence in patients with schizophrenia
por: Joe, Soohyun, et al.
Publicado: (2016)

Iminodibenzyl class antipsychotics for schizophrenia: a systematic review and meta-analysis of carpipramine, clocapramine, and mosapramine
por: Kishi, Taro, et al.
Publicado: (2014)

Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: a network meta-analysis in a Japanese population
por: Kishi, Taro, et al.
Publicado: (2017)

PM441. Long term atypical antipsychotic treatment improves cognitive performance in schizophrenia but not surpassing conventional antipsychotic drugs effects.
por: Vera, Gabriel Selva, et al.
Publicado: (2016)

PM379. Quality of Life in patients with schizophrenia or bipolar disorder receiving long-acting antipsychotics
por: Lin, Shih-Ku
Publicado: (2016)

PM399. Attitudes toward antipsychotic long-acting injections among patients with Schizophrenia in Japan.
por: Kudo, Shuhei, et al.
Publicado: (2016)

PM524. VEGF may have a neuroprotective role in the improvement of schizophrenia or in the treatment effects of antipsychotics
por: Kim, Yongku, et al.
Publicado: (2016)

Fluvoxamine for blonanserin-associated akathisia in patients with schizophrenia: report of five cases
por: Furuse, Tsutomu, et al.
Publicado: (2010)

Blonanserin-induced Mood Alteration in Schizophrenia and Schizoaffective Disorder: Two Cases
por: Min, Aran, et al.
Publicado: (2013)

Simultaneous Comparison of Efficacy and Tolerability of Second-Generation Antipsychotics in Schizophrenia: Mixed-Treatment Comparison Analysis Based on Head-to-Head Trial Data
por: Oh, Gyu Han, et al.
Publicado: (2015)

T234. BREAKTHROUGH ON ANTIPSYCHOTIC MAINTENANCE MEDICATION: A STUDY-LEVEL META-ANALYSIS AND META-REGRESSION ANALYSIS
por: Rubio, Jose, et al.
Publicado: (2018)

PM430. Blonanserin reversed phencyclidine-induced novel object recognition deficit and induced cortical dopamine and acetylcholine efflux through dopamine D(3) receptor antagonism
por: Miyauchi, Masanori, et al.
Publicado: (2016)

PM417. Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning: a post-hoc analysis of QUALIFY, a head-to-head study in schizophrenia
por: Salzman, Phyllis, et al.
Publicado: (2016)

PM403. Comparison between addition of and switching to aripiprazole for resolving antipsychotic-induced hyperprolactinemia
por: Lee, Jung Suk, et al.
Publicado: (2016)

PT592. Memantine Monotherapy for Alzheimer’s Disease: A Systematic Review and Meta-analysis
por: Matsunaga, Shinji, et al.
Publicado: (2016)

PM387. A preliminary study of antipsychotics polypharmacy among schizophrenia patients who admitted to national mental hospital
por: Han, Jaewook
Publicado: (2016)

A case of schizophrenia with relapsed catatonia successfully treated with blonanserin transdermal patch
por: Hagikura, Minako, et al.
Publicado: (2023)

397. Long-Term Mortality of HIV Patients Following Cryptococcal Infection
por: Hevey, Matthew, et al.
Publicado: (2018)

T28. BENEFITS AND HARMS OF ANTIPSYCHOTICS IN THE TREATMENT OF CHILDREN AND ADOLESCENTS WITH SCHIZOPHRENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Hagi, Katsuhiko, et al.
Publicado: (2020)

Antidepressive Effect of Antipsychotics in the Treatment of Schizophrenia: Meta-Regression Analysis of Randomized Placebo-Controlled Trials
por: Miura, Itaru, et al.
Publicado: (2020)

PM527. Higher serum concentrations of tyrosine and glutamate in schizophrenia patients treated with clozapine, compared to in those treated with conventional antipsychotics
por: Melkersson, Kristina, et al.
Publicado: (2016)

Switching from blonanserin tablets to blonanserin transdermal patches improves tardive dyskinesia: A case report
por: Sakai, Shintaro, et al.
Publicado: (2021)

Effect of blonanserin on cognitive and social function in acute phase Japanese schizophrenia compared with risperidone
por: Hori, Hikaru, et al.
Publicado: (2014)

PM382. Use of atypical antipsychotics and risks of cataract development in patients with schizophrenia: A population-based, nested case-control study.
por: Chou, Po-Han, et al.
Publicado: (2016)

PM398. Fluctuations in hallucinatory experiences within a day in relation to dopamine D2 receptor blockade with antipsychotics in patients with schizophrenia
por: Koizumi, Teruki, et al.
Publicado: (2016)

Efficacy and safety of blonanserin versus risperidone in the treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials
por: Deng, Shu-Wen, et al.
Publicado: (2023)

PM428. Combination of Clozapine with Long Acting Injectable Antipsychotics in Treatment Resistant Schizophrenia: Preliminary Evidence from Health Care Utilization Indices
por: Grimminck, Rachel, et al.
Publicado: (2016)

Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study
por: Iwata, Nakao, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_37iml9iti42iac01lfepj8gs21